Arming Synthetic Bacteria Against Cancer

Researchers engineer bacteria that deliver an anti-tumor toxin in mice before self-destructing.

Written byAnna Azvolinsky
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Schematic of the microfluidic device used to co-culture engineered bacteria and cancer cells (top). Live co-culture of engineered bacteria and cancer cells immediately before and after the synchronized lysis event, showing cancer cell death (bottom left, right, respectively).JEFF HASTY, UC SAN DIEGOA synthetic genetic circuit programmed into an attenuated Salmonella enterica subspecies can be used to systemically deliver an anti-tumor toxin into mice with cancer. The circuit allows the bacterial cells inside a tumor to synchronously self-destruct by lysis, releasing the toxin directly in the tumor. The treatment of mice with the engineered bacteria is described by researchers at the University of California, San Diego (UCSD), today (July 20) in Nature, pointing to a way to harness bacteria for cancer drug delivery.

“This impressive study represents a big step towards one of the great dreams of synthetic biology: rationally programming cells, in this case bacteria, to exhibit complex, dynamic, and beneficial behaviors in a host organism,” Michael Elowitz, whose Caltech lab builds synthetic genetic circuits and who was not involved in the work, wrote in an email to The Scientist.

Bert Vogelstein, a cancer geneticist at the Johns Hopkins’ Sidney Kimmel Cancer Center in Baltimore who also was not involved in the work, agreed. “This paper describes a highly innovative strategy employing synthetic biology to weaponize bacteria and shows that these bacteria can be used to slow the growth of tumors growing in mice,” he wrote in an email to The Scientist.

The idea of using bacteria ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies